Oscar & Paul

Founded in 2019, DeepLife is a biotechnology company based in Paris, France. It specializes in developing digital twins of cells to accelerate drug discovery. The company uses advanced modeling techniques and deep learning on multi-omics data to simulate cell responses and identify new targets, biomarkers, and potential drug candidates.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.